The impact of chronic kidney disease on muscle tissue metabolism in patients undergoing hemodialysis

Objective: to estimate the prevalence of sarcopenia and evaluate the contribution of myostatin and mTOR to the development of muscle mass loss and strength in patients with end-stage renal disease treated with program hemodialysis. Materials and methods: the study included 80 patients with CKD5D, the average age of study participants was 51.7±11.6 years. In all patients, anamnestic data were analyzed, the results of laboratory and instrumental examination were evaluated, the levels of myostatin and mTOR in the blood serum were determined, hand dynamometry, bioimpedancemetry, and a leg raising test were performed. Results: the average volume of muscle mass in the subgroup with sarcopenia was 20.5±0.7 kg and significantly differed from that in the subgroup without sarcopenia 25.23±0.8 kg (p <0.05). The prevalence of sarcopenia in the general group was 38.75%. In men, decreased muscle mass was statistically significantly more common than among women (p <0.05). The level of mTOR in the blood serum of patients with sarcopenia was significantly lower than that in the subgroup without sarcopenia (6.61±0.4 ng/ml and 9.4±0.3 ng/ml, respectively (p <0.001)). The level of myostatin was significantly higher in the subgroup of patients with sarcopenia than without it (12.2±0.6 ng/ml vs. 8.1±0.3 ng/ml, respectively (p <0.001)). The increase in myostatin was accompanied by a decrease in mTOR both in the general group (r=-0.57) and in the subgroup of patients with sarcopenia (r=-0.55). Conclusion: A high prevalence of sarcopenia was found in patients with CKD receiving renal replacement therapy. Myostatin and mTOR have demonstrated their diagnostic potential and can be used as promising markers for the verification of sarcopenia.

1. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.

2. Есаян А.М., Арутюнов Г.П., Мелихов О.Г. Распространенность хронической болезни почек среди пациентов, обратившихся в учреждения первичной медико-санитарной помощи. Результаты проспективного наблюдательного исследования в 12 регионах России. Клиническая нефрология. 2021;3:6-16. DOI: 10.18565/nephrology.2021.3.6-16.

3. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. DOI: 10.1016/j.kint.2020.06.019.

4. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. DOI: 10.1016/j.kint.2020.11.003.

5. Томилина Н.А., Андрусев А.М., Перегудова Н.Г., Шинкарев М.Б. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 20102015 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества, Часть первая. Нефрология и диализ. 2017;19(4):1-95. DOI: 10.28996/1680-4422-2017-4suppl-1-95.

6. Котенко О.Н., Васина Н.В., Марченкова Л.В., Лысенко М.А. Состояние заместительной терапии хронической почечной недостаточности в Москве в 2015-2020 гг. Клиническая нефрология. 2021;13(1):13-19. DOI: 10.18565/nephrology.2021.1.13-19.

7. Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347-1372. DOI: 10.1007/s40620-020-00840-y.

8. Соколова А.В., Драгунов Д.О., Арутюнов Г.П., Митрохин В.М. Прогностическое значение саркопении у пациентов с ХБП. Клиническая нефрология. 2019;1:48-55. DOI: 10.18565/nephrology.2019.1.48-55.

9. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-2646. DOI: 10.1016/S0140-6736(19)31138-9. Epub 2019 Jun 3. Erratum in: Lancet. 2019;393(10191):2590. PMID: 31171417.

10. Carvalho do Nascimento PR, Poitras S, Bilodeau M. How do we define and measure sarcopenia? Protocol for a systematic review. Syst Rev. 2018;7(1):51. DOI: 10.1186/s13643-018-0712-y.

11. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019;48(4):601. PMID: 30312372; PMCID: PMC6322506.

12. Souza VA, Oliveira D, Barbosa SR, Correa JODA, Colugnati FAB, Mansur HN, et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors. PLoS One. 2017;12(4):e0176230. DOI: 10.1371/journal.pone.0176230.

13. Лаврищева Ю.В., Румянцев А.Ш., Захаров М.В., Кулаева Н.Н., Сомова В.М. Саркопения - актуальная проблема при хронической болезни почек 5д стадии. Нефрология. 2020;24(1):60-66. DOI: 10.36485/1561-6274-2020-24-1-60-66.

14. Смирнов А.В., Голубев Р.В., Коростелева Н.Ю., Румянцев А.Ш. Снижение физической работоспособности у больных, получающих заместительную почечную терапию: фокус на саркопению. Нефрология. 2017;21(4):9-29. DOI: 10.24884/1561-6274-2017-21-4-9-29

15. Борханова Э.Г., Исламова Г.М., Максудова А.Н. Частота нарушений питания у пациентов пожилого и старческого возраста с хронической болезнью почек. Практическая медицина. 2021;19(4):89-92. eLIBRARY ID: 47311783.

16. Moorthi RN, Avin KG. Clinical relevance of sarcopenia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(3):219-228. DOI: 10.1097/MNH.0000000000000318.

17. Сафроненко В.А., Чесникова А.И., Сафроненко А.В., Скаржин-ская Н.С., Кузнецов И.И., Насытко А.Д. Клинические особенности хронической сердечной недостаточности у пациентов с артериальной гипертензией и синдромом старческой астении: наблюдательное кросс-секционное исследование. Кубанский научный медицинский вестник. 2021;28(4):25-40. DOI: 10.25207/1608-6228-2021-28-4-25-40.

18. Sato E, Mori T, Mishima E, Suzuki A, Sugawara S, Kurasawa N, et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep. 2016;6:36618. DOI: 10.1038/srep36618.

19. Асанбек А.К., Сезер С. Две стороны одной медали: роль недостаточного и избыточного веса в патогенезе хронической болезни почек. Нефрология и диализ. 2019;21(3):292-300. DOI: 10.28996/2618-9801-2019-3-292-300.

20. Wang DT, Yang YJ, Huang RH, Zhang ZH, Lin X. Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease. Oxid Med Cell Longev. 2015;2015:684965. DOI: 10.1155/2015/684965.

21. Bataille S, Chauveau P, Fouque D, Aparicio M, Koppe L. Myostatin and muscle atrophy during chronic kidney disease. Nephrol Dial Transplant. 2021;36(11):1986-1993. DOI: 10.1093/ndt/gfaa129.

22. Tan KT, Ang SJ, Tsai SY. Sarcopenia: Tilting the Balance of Protein Homeostasis. Proteomics. 2020;20(5-6):e1800411. DOI: 10.1002/pmic.201800411.

23. Liu J, Pan M, Huang D, Guo Y, Yang M, Zhang W, et al. Myostatin-1 Inhibits Cell Proliferation by Inhibiting the mTOR Signal Pathway and MRFs, and Activating the Ubiquitin-Proteasomal System in Skeletal Muscle Cells of Japanese Flounder Paralichthys olivaceus. Cells. 2020;9(11):2376. DOI: 10.3390/cells9112376.

24. Zhang YY, Gu LJ, Huang J, Cai MC, Yu HL, Zhang W, et al. CKD autophagy activation and skeletal muscle atrophy-a preliminary study of mitophagy and inflammation. Eur J Clin Nutr. 2019;73(6):950-960. DOI: 10.1038/s41430-018-0381-x

25. Hirai K, Ookawara S, Morishita Y. Sarcopenia and Physical Inactivity in Patients With Chronic Kidney Disease. Nephrourol Mon. 2016;8(3):e37443. DOI: 10.5812/numonthly.37443.

26. Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr. 2007;86(3):633-8. DOI: 10.1093/ajcn/86.3.633.